Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM

No authors listed

Published Erratum

No authors listed. Neurology. 2025.

. 2025 Jan 14;104(1):e210145.

doi: 10.1212/WNL.0000000000210145. Epub 2024 Dec 9.

No abstract available

Erratum for

Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM.
Pack AM, Oskoui M, Williams Roberson S, Donley DK, French J, Gerard EE, Gloss D, Miller WR, Munger Clary HM, Osmundson SS, McFadden B, Parratt K, Pennell PB, Saade G, Smith DB, Sullivan K, Thomas SV, Tomson T, Dolan O'Brien M, Botchway-Doe K, Silsbee HM, Keezer MR. Pack AM, et al. Neurology. 2024 Jun;102(11):e209279. doi: 10.1212/WNL.0000000000209279. Epub 2024 May 15. Neurology. 2024. PMID: 38748979 Free PMC article.

1. Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline from the AAN, AES, and SMFM. Neurology. 2024;102(11):e209279. doi: 10.1212/WNL.0000000000209279 - DOI - PMC - PubMed